Huey-Wen Hsiao

Title: Innovations by Inventor Huey-Wen Hsiao

Introduction

Huey-Wen Hsiao is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of immunotherapy, particularly in the development of antibodies that target specific proteins involved in immune regulation. With a total of 2 patents, Hsiao's work is paving the way for new treatments in cancer therapy.

Latest Patents

Hsiao's latest patents include innovative approaches to cancer treatment through the use of anti-PD-L1 antibodies and anti-PD-L1/IL10 fusion proteins. These antibodies specifically bind to the human PD-L1 protein, effectively decreasing and blocking immune regulatory effects mediated by PD-L1. This mechanism is crucial in the tumor microenvironment, as it can inhibit the binding of PD-L1 to the immune checkpoint molecule PD-1. Additionally, the fusion with IL10 can enhance CD8+ T-cell cytotoxicity, providing a promising avenue for treating various diseases responsive to immune regulation.

Another significant patent involves anti-colony stimulating factor 1 receptor (CSF1R) antibodies. These antibodies also specifically bind to the human CSF1 receptor protein, aiming to inhibit immune regulatory effects mediated by CSF1R. Similar to his previous work, these antibodies include fusions with IL10, which can activate CD8+ T-cell cytotoxicity in the tumor microenvironment. The methods outlined in this patent offer potential treatments for conditions that require modulation of immune regulatory functions.

Career Highlights

Huey-Wen Hsiao is currently associated with Elixiron Immunotherapeutics (Hong Kong) Limited, where he continues to innovate in the field of immunotherapy. His research focuses on developing effective treatments that harness the body's immune system to combat cancer. Hsiao's work is characterized by a commitment to advancing medical science and improving patient outcomes.

Collaborations

Hsiao collaborates with notable colleagues, including Hung-Kai Chen and Hong-Sen Chen. These partnerships enhance the research and development efforts at Elixiron Immunotherapeutics, fostering an environment of innovation and discovery.

Conclusion

Huey-Wen Hsiao's contributions to immunotherapy through his patents and collaborative efforts are significant in the fight against cancer. His innovative approaches to antibody development are paving the way for new therapeutic strategies that could transform patient care